StonvexLoading…
StonvexStonvexStonvexCore line items from DKS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2026 2026-01-31 | Annual 2025 2025-02-01 | Annual 2024 2024-02-03 | Annual 2023 2023-01-28 |
|---|---|---|---|---|
Revenue | $17.22B | $13.44B | $12.98B | $12.37B |
Operating Income | $1.10B | $1.47B | $1.28B | $1.46B |
Net Income | $849.24M | $1.17B | $1.05B | $1.04B |
EPS (Diluted) | $9.97 | $14.05 | $12.18 | $10.78 |
Total Assets | $17.41B | $10.46B | $9.31B | $8.99B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $1.35B | $1.69B | $1.80B | $1.92B |
Free Cash Flow OCF − CapEx | $400.17M | $509.27M | $939.91M | $557.81M |
Shares Outstanding | 85.14M | 82.93M | 85.92M | 99.27M |